Filing Details

Accession Number:
0001641172-25-002493
Form Type:
13D Filing
Publication Date:
2025-04-01 20:00:00
Filed By:
Heng Fai Ambrose Chan
Company:
Impact Biomedical Inc.
Filing Date:
2025-04-02
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Heng Fai Ambrose Chan 0 2,041,248 0 2,041,248 2,041,248 16.9%
Alset Inc. 0 2,041,248 0 2,041,248 2,041,248 16.9%
Alset International Limited 0 1,307,190 0 1,307,190 1,307,190 10.8%
Global Biomedical Pte. Ltd. 0 453,286 0 453,286 453,286 3.8%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
Mr. Chan is, personally and through an entity he controls, the majority shareholder of Alset Inc., and the Chairman and Chief Executive Officer of Alset Inc. Alset International Limited is a majority owned subsidiary of Alset Inc. Mr. Chan may be deemed to be the beneficial owner of an aggregate of 2,041,248 shares of common stock through the following entities: (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd. (a subsidiary of Alset International Limited); (b) 853,904 shares of common stock held by Alset International Limited; and (c) 734,058 shares of common stock held by Alset Inc. The percentages set forth above are based on 12,085,412 shares of the Issuer's common stock outstanding as of April 2, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
Consists of 734,058 shares of common stock held by Alset Inc. directly, and shares held by its subsidiaries including (a) 453,286 shares of common stock held by Global Biomedical Pte. Ltd.; and (b) 853,904 shares of common stock held by Alset International Limited. The percentages set forth above are based on 12,085,412 shares of the Issuer's common stock outstanding as of April 2, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
Includes 853,904 shares of common stock held directly by Alset International Limited and 453,286 shares of common stock held by its subsidiary Global Biomedical Pte. Ltd. The percentages set forth above are based on 12,085,412 shares of the Issuer's common stock outstanding as of April 2, 2025.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentages set forth above are based on 12,085,412 shares of the Issuer's common stock outstanding as of April 2, 2025.


SCHEDULE 13D

 
Heng Fai Ambrose Chan
 
Signature:/s/ Heng Fai Ambrose Chan
Name/Title:Heng Fai Ambrose Chan, an Individual
Date:04/02/2025
 
Alset Inc.
 
Signature:/s/ Heng Fai Ambrose Chan
Name/Title:Heng Fai Ambrose Chan, Chief Executive Officer, Alset Inc.
Date:04/02/2025
 
Alset International Limited
 
Signature:/s/ Heng Fai Ambrose Chan
Name/Title:Heng Fai Ambrose Chan, Chief Executive Officer, Alset International Limited
Date:04/02/2025
 
Global Biomedical Pte. Ltd.
 
Signature:/s/ Heng Fai Ambrose Chan
Name/Title:Heng Fai Ambrose Chan, Director, Global Biomedical Pte. Ltd.
Date:04/02/2025